Diakonos Oncology Set to Shine at the Upcoming Biotech Showcase
HOUSTON — Diakonos Oncology Corp., a pioneering clinical-stage biotechnology firm focused on innovative immunotherapies, is poised to showcase its advancements at the Biotech Showcase. This highly anticipated event will take place in San Francisco from January 13-15, 2026, uniting various private and mid-cap biotechnology enterprises to present new developments and engage with investors.
Leadership Representation at the Showcase
At the forefront of Diakonos Oncology's representation will be Jay Hartenbach, the company's President and COO. Hartenbach is slated to present insights into the latest breakthroughs involving DOC1021, a groundbreaking investigational therapy designed specifically for aggressive cancers. This first-in-class treatment leverages a distinctive approach involving patient-derived, double-loaded dendritic cells, signaling a new direction in cancer care.
Moreover, Hartenbach will participate in a panel discussion featuring leading executives from the biotechnology sector, where they will explore how advancements in technology are reshaping the landscape of cell and gene therapies.
Innovative Approaches to Cancer Treatment
“Diakonos is advancing immunotherapy through our innovative double-loading dendritic cell treatments that harness the body's immune system to target cancer with specificity and rigor,” stated Hartenbach. “I am both honored to participate in this vital conversation about the breakthroughs transforming medicine and eager to present Diakonos' leadership in the field.”
Event Details and Presentation Highlights
The company presentation by Diakonos Oncology is set for January 12, 2026, at 2:15 PM Pacific Standard Time. This session will take place at the Franciscan B ballroom in the Hilton Union Square. An engaging panel titled "Engineering the Future: Advances in Cell and Gene Therapies" will occur on January 13, from 8:00 to 9:00 AM, also at Hilton Union Square. The discussion will focus on transformative technologies that are creating new horizons in cancer therapy.
Diakonos management is keen to network during the showcase and invites interested parties to schedule one-on-one meetings to discuss potential collaborations and innovations.
About DOC1021: A New Era in Immunotherapy
DOC1021 represents a cutting-edge, patient-derived therapy that integrates tumor lysate with amplified tumor-derived mRNA. This unique combination of dendritic cells, mRNA, and proteins is made from fresh patient tumor specimens, mimicking a natural viral infection to trigger a robust immune response. The methodology enhances the immune system's ability to target cancer cells effectively without extensive modifications to the patient’s own immune cells.
Diakonos is currently conducting two active clinical trials with DOC1021, including a Phase 1 study focusing on pancreatic cancer and a Phase 2 study addressing glioblastoma. Significant progress has been made, with Fast Track designations granted by the FDA for both programs, facilitating an accelerated pathway for drug development.
Company Commitment to Innovation
Diakonos Oncology, based in Houston, is dedicated to advancing the field of cancer immunotherapy with its patented dendritic cell therapeutic platform. This innovative approach is thoughtfully designed to address the urgent, unmet medical needs encountered in late-stage and aggressive cancers. Continued research aims at improving patient outcomes through effective and targeted cancer treatment solutions.
Frequently Asked Questions
What is the Biotech Showcase?
The Biotech Showcase is an event that gathers private and mid-cap biotechnology companies to showcase innovations and connect with investors and executives in the biopharmaceutical sector.
Who from Diakonos Oncology will present at the event?
Jay Hartenbach, the President and COO of Diakonos Oncology, will present the latest developments related to DOC1021 and participate in a panel discussion.
What is DOC1021?
DOC1021 is Diakonos Oncology's investigational therapy that uses patient-derived dendritic cells combined with tumor lysate and mRNA to target aggressive cancers.
What recent recognitions has Diakonos received?
Diakonos Oncology has received Fast Track designations from the FDA for their clinical trials in pancreatic cancer and glioblastoma.
Where can more information about Diakonos Oncology be found?
For further details about the company and its innovations in cancer therapy, visit their official website.
